$BPTH
BIO-PATH HOLDINGS, INC.

2014 Q4 Form 10-Q Financial Statement

#000114420414068781 Filed on November 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $870.0K $710.0K $340.0K
YoY Change 155.88% -12.35% 30.77%
% of Gross Profit
Research & Development $1.630M $424.5K $410.0K
YoY Change 297.67% -25.34% 355.56%
% of Gross Profit
Depreciation & Amortization $50.00K $40.00K $40.00K
YoY Change 25.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.603M $1.154M $791.0K
YoY Change 102.68% -17.19% 83.94%
Operating Profit -$1.603M -$1.154M -$791.0K
YoY Change 102.68% -17.19%
Interest Expense $10.00K $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.240K $5.699K $1.396K
YoY Change 275.36% 993.86%
Pretax Income -$1.600M -$1.150M -$790.0K
YoY Change 102.53% -17.27% 83.72%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.598M -$1.148M -$789.6K
YoY Change 102.38% -17.57% 83.62%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.556M -$2.556M -$1.927M
COMMON SHARES
Basic Shares Outstanding 89.24M shares 89.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.86M $14.64M $3.550M
YoY Change 290.42% 257.07% 569.81%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $100.5K $290.0K $64.12K
YoY Change 56.74% 45.0% 50.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.11M $14.93M $3.667M
YoY Change 284.86% 247.21% 375.27%
LONG-TERM ASSETS
Property, Plant & Equipment $113.1K $0.00
YoY Change
Goodwill
YoY Change
Intangibles $1.251M $1.291M $1.412M
YoY Change -11.38% -10.22%
Long-Term Investments
YoY Change
Other Assets $70.00K
YoY Change
Total Long-Term Assets $1.364M $66.12K $0.00
YoY Change -95.44% -100.0%
TOTAL ASSETS
Total Short-Term Assets $14.11M $14.93M $3.667M
Total Long-Term Assets $1.364M $66.12K $0.00
Total Assets $15.48M $16.28M $5.079M
YoY Change 204.75% 183.21% 116.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $41.03K $88.51K $76.11K
YoY Change -46.1% 121.29% 33.52%
Accrued Expenses $253.4K $190.0K $66.74K
YoY Change 279.76% 46.15% -51.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $562.0K $280.0K $294.9K
YoY Change 90.56% 64.71% -10.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $562.0K $280.0K $294.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $562.0K $280.0K $294.9K
YoY Change 90.56% 64.71% -10.43%
SHAREHOLDERS EQUITY
Retained Earnings -$19.92M
YoY Change
Common Stock $89.76K $84.24K
YoY Change 6.56% 35.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.92M $16.00M $4.783M
YoY Change
Total Liabilities & Shareholders Equity $15.48M $16.28M $5.079M
YoY Change 204.75% 183.21% 116.7%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income -$1.598M -$1.148M -$789.6K
YoY Change 102.38% -17.57% 83.62%
Depreciation, Depletion And Amortization $50.00K $40.00K $40.00K
YoY Change 25.0% 0.0% 0.0%
Cash From Operating Activities -$1.160M -$1.020M -$470.0K
YoY Change 146.81% 41.67% 11.9%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$70.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$50.00K -$70.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 440.0K 0.000 -70.00K
YoY Change -728.57% -100.0% -111.11%
NET CHANGE
Cash From Operating Activities -1.160M -1.020M -470.0K
Cash From Investing Activities -50.00K -70.00K 0.000
Cash From Financing Activities 440.0K 0.000 -70.00K
Net Change In Cash -770.0K -1.090M -540.0K
YoY Change 42.59% -150.46% -357.14%
FREE CASH FLOW
Cash From Operating Activities -$1.160M -$1.020M -$470.0K
Capital Expenditures -$50.00K -$70.00K $0.00
Free Cash Flow -$1.110M -$950.0K -$470.0K
YoY Change 136.17% 31.94% 11.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Assets
Assets
16284519 USD
CY2013Q4 us-gaap Assets
Assets
5078831 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
88514 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
76109 USD
CY2014Q3 us-gaap Revenues
Revenues
0 USD
CY2014Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
66124 USD
CY2013Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
0 USD
CY2014Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1291049 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1411518 USD
CY2011 bpth Percentage Of Change In Depreciation Amortization Of Intangible Assets And Asset Impairment And Other Charges Operating
PercentageOfChangeInDepreciationAmortizationOfIntangibleAssetsAndAssetImpairmentAndOtherChargesOperating
0.5 pure
CY2012Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
345000 USD
CY2013Q4 bpth Authorised Capital To Be Raised
AuthorisedCapitalToBeRaised
100000000 USD
CY2014Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15000000 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13800000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
34231482 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
84238 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16284519 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1048716 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1125711 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
713352 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
810152 USD
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
1393728 USD
CY2014Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
18319359 USD
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
15397296 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
us-gaap Operating Income Loss
OperatingIncomeLoss
-2939121 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2478284 USD
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5713 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
837 USD
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001133818
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
BPTH
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89237872 shares
CY2013Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
424521 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
568576 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1848751 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1290506 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
1154108 USD
us-gaap Operating Expenses
OperatingExpenses
2939121 USD
us-gaap Operating Expenses
OperatingExpenses
2478284 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1154108 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1393728 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17353 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
2492 USD
CY2014Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
14 USD
CY2013Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
316 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
295 USD
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
661 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5699 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
521 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17058 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1831 USD
us-gaap Net Income Loss
NetIncomeLoss
-2922063 USD
us-gaap Net Income Loss
NetIncomeLoss
-2476453 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89237872 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75380214 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89237872 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68068456 shares
CY2014Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
40156 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
120469 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
120469 USD
us-gaap Share Based Compensation
ShareBasedCompensation
327118 USD
us-gaap Share Based Compensation
ShareBasedCompensation
635603 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
45199 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-46699 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
130064 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
7138 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11740 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-155491 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2661479 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1836311 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66124 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-66124 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13812373 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5403106 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13812373 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5403106 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
11084770 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
3566795 USD
CY2012Q4 us-gaap Cash
Cash
534046 USD
CY2013Q3 us-gaap Cash
Cash
4100841 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89237872 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89237872 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84237872 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84237872 shares
CY2014Q3 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
88514 USD
CY2014Q3 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
31770 USD
CY2013Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
76109 USD
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
489501 shares
CY2014Q1 bpth Issuance Of Common Stock And Warrants Shares
IssuanceOfCommonStockAndWarrantsShares
5000000 shares
CY2014Q1 bpth Common Stock Repurchased Shares
CommonStockRepurchasedShares
2500000 shares
CY2014Q1 bpth Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
15000000 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.74
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
50000 USD
us-gaap Cost Of Reimbursable Expense
CostOfReimbursableExpense
50000 USD
CY2014Q3 bpth Accrued Patent Expense Current
AccruedPatentExpenseCurrent
25000 USD
bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
370000 USD
CY2014Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
118047 USD
CY2014Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.42
bpth Supply Agreement Consideration To Be Paid In Stages
SupplyAgreementConsiderationToBePaidInStages
150000 USD
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD

Files In Submission

Name View Source Status
0001144204-14-068781-index-headers.html Edgar Link pending
0001144204-14-068781-index.html Edgar Link pending
0001144204-14-068781.txt Edgar Link pending
0001144204-14-068781-xbrl.zip Edgar Link pending
bpth-20140930.xml Edgar Link completed
bpth-20140930.xsd Edgar Link pending
bpth-20140930_cal.xml Edgar Link unprocessable
bpth-20140930_def.xml Edgar Link unprocessable
bpth-20140930_lab.xml Edgar Link unprocessable
bpth-20140930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v393729_10q.htm Edgar Link pending
v393729_ex31.htm Edgar Link pending
v393729_ex32.htm Edgar Link pending